Hepatitis B Treatment Market Size

Hepatitis B Treatment Market size was over USD 88.71 billion in 2023 and is likely to reach USD 155.27 billion by the end of 2036, growing at around 4.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of hepatitis B treatment is assessed at USD 91.83 billion.

The growth of the hepatitis B treatment market can be attributed primarily to the growing number of individuals who are infected by the hepatitis B virus, along with the need amongst the individuals to cure the viral infection.

Hepatitis is referred to as an inflammatory condition of the liver and is commonly caused by a hepatitis virus. The most common hepatotropic viruses that cause hepatitis are hepatitis A, B, C, D, and E. Hepatitis B is caused by Hepatitis B virus (HBV) which belongs to the viral family Hepadnaviridae.  Viral hepatitis B infections are diagnosed by the use of virus testing diagnostic kits, whereas for non-viral infections, blood tests, liver ultrasound or liver biopsy tests are performed. Recently, with the advancements in medical sciences, rapid testing kits are also being used widely by medical practitioners for the detection of the disease. The treatment of hepatitis B is done by the use of the hepatitis B vaccine or through anti-viral drugs. Though, several players are still in search of developing a new cure for hepatitis B, and few of them are in the development of new drugs and medicines for hepatitis B, as the treatment developed for hepatitis B doesn’t totally eradicate the virus from the human body. Hepatitis B is transmitted commonly through direct contact with infected blood, especially during unsterile healthcare practices, or while giving birth to the newborn by the mother, who is a hepatitis B carrier. Hepatitis B is also transmitted through unprotected sexual intercourse or contact with bodily fluids. Hepatitis B infection in human beings can be either acute or chronic. The United States Food and Drug Administration (FDA) has approved eight different treatment options for the treatment of chronic hepatitis B. These include treatment with tenofovir alafenamide, adefovir, entecavir, pegylated interferon, tenofovir disoproxil, telbivudine, alpha-interferon, and lamivudine.